Trials / Completed
CompletedNCT04877769
Bronchopulmonary PK of AT-527 (R07496998)
A Phase 1, Open-label, Randomized Study in Healthy Subjects to Assess the Bronchopulmonary Pharmacokinetics, Safety and Tolerability of AT-527, a Potential Treatment for COVID-19
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-527 | administered twice daily (BID) for 2.5 days (5 doses in total) |
Timeline
- Start date
- 2021-04-25
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2021-05-07
- Last updated
- 2022-02-25
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04877769. Inclusion in this directory is not an endorsement.